PPMD and NS Pharma hosted a community webinar on March 2, 2023 to discuss VILTEPSO, an FDA-approved treatment for patients with Duchenne amenable to exon 53 skipping. Mathula Thangarajh, MD joined us to discuss the clinical evidence to support the early initiation of treatments in Duchenne, and provide an overview of the role of exon skipping. Dr. Thangarajh also described the safety and tolerability profile of VILTEPSO, and discussed the efficacy of VILTEPSO for the treatment of Duchenne. Note: This recording contains edit to content as requested by the company.